Table 1

Overview and characteristics of included studies
Study No.of patients Mean age Male Ischemic etiology Mean NYHA Mean LVEF ACEI/ARB β-blocker Statins EPA + DHA dose EPA dose DHA dose EPA/DHA Duration Placebo Study design Quality score
y % % % % % % mg/d mg/d mg/d months
Mehra 2006 14 60 71 43 III-IV 17 93 64 0 5440 3520 1920 1.83 4 Corn oil R, DB, PC 3
O'Keefe 2006 18 68 100 100 NR NR NR 78 83 810 225 585 0.38 4 Corn oil & olive oil R, DB, PC, CO 3
Nodari 2009 44 63 91 0 II-III 36.2 100 100 NR 1440 540 900 0.60 6 Olive oil R, DB, PC 3
Zhao 2009 75 73 73 64 II-III 31 100 87 NR 600 360 240 1.50 3 NR R, SB, PC 3
Eschen 2010 138 60 86 68 II-III 32 95 88 54 900 490 410 1.20 6 Olive oil R, DB, PC 3
Moertl 2011 a 22 57 83 0 III-IV 24.3 100 100 NR 840 465 375 1.24 3 Gelatin R, DB, PC 5
Moertl 2011 b 21 60 94 0 III-IV 24.2 100 100 NR 3360 1860 1500 1.24 3 Gelatin R, DB, PC 5
Nodari 2011 133 63 75 0 I-II 36.5 100 100 14 1950 730 1220 0.60 12 Olive oil R, DB, PC 3

The study by Moertl et al. includes two intervention groups of different dosages of EPA + DHA (Moertl 2011a, EPA + DHA 840 mg/day and Moertl 2011b, EPA + DHA 3360 mg/day).

NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; EPA, eicosapentaenoic acid; DHA, ducosahexenoic acid; R, random; DB, double blind; SB, single blind; PC, placebo-controlled; CO, crossover; NR, not reported.

Xin et al.

Xin et al. BMC Cardiovascular Disorders 2012 12:77   doi:10.1186/1471-2261-12-77

Open Data